[Double-blind study of tiapride and placebo in patients with subcontinuous essential headache].
25 patients with subcontinual primary headache were treated with Tiapride an Placebo in a controlled double-blind study. The duration of trial was 13 weeks. Blood samples were taken to value PRL in 10 patients and in 10 normal subjects. During the pharmacological trial no side-effects appeared. Authors refer results elaborated through statistical examinations. Tiapride is useful to reduce the frequency of the attacks (in 65% of the patients) with percentage of improvement statistically significant in comparison with placebo. Headache index appears influenced although in non statistically significant way.
D000328:Adult; D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011388:Prolactin / Q000097:blood; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*; D014653:Vascular Headaches / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D001549:Benzamides; D010919:Placebos; D011388:Prolactin; D013976:Tiapamil Hydrochloride
Studio in doppio cieco coi tiapride versus placebo in pazienti con cefalea essenziale sub-continua.